Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
custirsen
- Development stage
- Phase 3
- Lead developer
- Sonus Pharmaceuticals
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Custirsen is a second-generation antisense oligonucleotide designed to inhibit the production of clusterin, a cytoprotective chaperone protein that is overexpressed in many cancers and associated with treatment resistance. By binding to the mRNA of the clusterin gene, custirsen reduces clusterin protein levels, thereby sensitizing tumor cells to chemotherapy and promoting apoptosis. It has been primarily investigated as an adjunct therapy for metastatic castration-resistant prostate cancer and advanced or metastatic non-small cell lung cancer. Custirsen is administered intravenously and has been studied in combination with chemotherapeutic agents such as docetaxel or cabazitaxel. The drug remains investigational and has not received regulatory approval.
- Brand names
- custirsen sodium
- Other names
- custirsen sodium
02
Targets
CLU (Clusterin)
Beyond the preview
Go deeper on custirsen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on custirsen.